This powerful blend of ingredients works to brighten and even out skin tone, while also promoting elasticity and reducing the appearance of wrinkles
August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
According to a review encompassing several clinical trials involving topical GHK-Cu, the peptide can provide several benefits for the skin, including [4]: Tightening loose skin Reversing thinning of aged skin Improving skin firmness, elasticity, and clarity Reducing fine lines and depth of wrinkles, and improving the structure of aged skin Smoothing rough skin and improve overall skin appearance Protecting against UV and photoaging Reducing photodamage, mottled hyperpigmentation, skin spots, and lesions One randomized controlled trial reported that compared to a control serum, GHK-Cu applied topically twice daily in the course of 8 weeks reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% in 40 female volunteers aged 40 to 65 years [17]
Inside our cells is the key to lifelong health and healing power that exceeds any manmade medicine on earth
